Blue Matter Blog
July 25, 2018
Part V in a Series on Rare Diseases At various points in this series, we’ve mentioned that rare disease treatments are usually quite expensive. In fact, the typical RD treatment costs between $300,000 and $750,000 (US) per year.1 Those high costs reflect two key realities: 1.) Developing new therapies is expensive and risky, and 2.) …
As a founder and managing partner, Ashwin brings 17+ years of life science consulting experience to Blue Matter. Prior to starting Blue Matter, he was Senior VP, Head of Brand Management / Business Development at Campbell Alliance. He is a physician and MBA by training and his specialties include product and portfolio strategy.
As a founder and managing partner of Blue Matter, Emily brings over 20 years of life science experience. Prior to Blue Matter, Emily was Senior VP and head of the San Francisco office for Campbell Alliance. Her specialties include product and portfolio strategy and oncology product launches.
As head of Blue Matter Europe, George brings extensive experience from 16+ years in life science consulting. Previously, George was GM / Head of Europe for Campbell Alliance. His specialties are commercial excellence, organizational design and customer engagement strategy.
Jeron brings 15+ years of life science experience, including more than 10 years in consulting. Previously, Jeron was Corporate Development and Commercial Excellence Lead at Campbell Alliance. His specialties include product, portfolio, and corporate strategy in oncology and diagnostics.
Thomas has 11+ years of experience in life science consulting (bio-pharma / diagnostic). He was formerly VP of Brand Management and Medical Affairs at Campbell Alliance. His specialties include product commercialization and Medical Affairs organization development in oncology and rare diseases.
Pankaj brings an impressive 25+ years of life science experience in industry and consulting to Blue Matter, having held increasingly senior positions at GSK, Bristol-Myers Squibb and Norgine. He was formerly Head of Consulting at IDEA, and he specializes in product, franchise and portfolio strategy, new product planning, and oncology launch readiness. He holds a BSc Pharm from UCL and an MBA from Imperial College London.
With over 10 years in research and consulting for the life sciences, Mary’s primary focus is on product strategy, franchise/portfolio strategy, launch planning, and commercial excellence in oncology and other TAs. She has a PhD in Biology from MIT and also hails from Campbell Alliance.
Dirk brings extensive industry experience to Blue Matter. His background spans 25+ years, with senior commercial roles in leading biopharmaceutical companies such as Shire, Roche / Genentech, and Amgen. His specialties include commercial strategy development, lifecycle management, and marketing, with a focus on rare diseases. He has a degree in biochemistry, as well as a PhD in Molecular Immunology from the University of Basel.
Alex has more than 12 years of experience consulting to life science companies. He brings deep expertise in market research and analytics, particularly related to commercial strategy development. Before joining Blue Matter, Alex spent three years at Campbell Alliance and five years at ZS Associates. He earned an MS degree in Management Science from Lehigh University and a degree in Engineering from Lafayette College.
Shankar brings strong scientific and commercial expertise to his consulting work. In his 8+ years in life sciences consulting, he has delivered broadly, including product launch and portfolio strategy across oncology and other therapeutic areas. Shankar earned a BA in Molecular and Cellular Biology from the University of California at Berkeley and a PhD in Biochemistry from MIT.